A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.

GlaxoSmithKline1 site in 1 country540 target enrollmentMay 25, 2007

ConditionsInfections, Papillomavirus

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Infections, Papillomavirus
Sponsor: GlaxoSmithKline
Enrollment: 540
Locations: 1
Primary Endpoint: Occurrence, intensity and relationship to vaccination of any solicited local or general symptoms
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb). This infection may go away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the AS04 adjuvant (control vaccine) and is also evaluating novel HPV vaccines formulations. This study will evaluate a novel GSK Biologicals' HPV vaccine (GSK1674330A) in terms of safety and immunogenicity compared to the control vaccine. There will be different levels of blinding in the study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Registry

clinicaltrials.gov

Start Date

May 25, 2007

End Date

October 13, 2008

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A woman whom the investigator believes can and will comply with the requirements of the protocol.
•A woman between, and including, 18 and 25 years of age at the time of the first vaccination.
•Written informed consent must be obtained from the subject prior to enrolment.
•Healthy subjects as established by medical history and clinical examination before entering into the study.
•Subject must be of non-childbearing potential, or if of child bearing potential, she must have a negative pregnancy test and she must be using adequate contraceptive precautions for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series.
•Subject who has had no more than 6 lifetime sexual partners prior to enrolment.

Exclusion Criteria

•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to six months after last dose of vaccine.
•Concurrently participating in another clinical study, at any time during the study period (up to six months after last dose of vaccine), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
•Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned during the study period up to one month after last dose of vaccine.
•Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0-29) the first dose of study vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
•Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study.
•A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose.
•Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
•Previous administration of components of the investigational vaccine
•Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines.
•Hypersensitivity to latex.

Outcomes

Primary Outcomes

Occurrence, intensity and relationship to vaccination of any solicited local or general symptoms

Time Frame: Within 7 days after each vaccine dose

Secondary Outcomes

Occurrence of clinically relevant abnormalities in biochemical and hematological parameters(Assessed at Month 0, one month and six months after the last dose of vaccine)
Occurrence of serious adverse events(Up to one month after the last dose of vaccine)
Occurrence, intensity and relationship to vaccination of any unsolicited symptom(Within 30 days after each vaccine dose)
Occurrence of serious adverse events during the extended safety follow-up(Up to six months after the last dose of vaccine)
Occurrence of pregnancy and pregnancy outcomes, new onset chronic diseases or medically significant conditions, regardless of causal relationship to vaccination(Throughout the study period (Month 0 up to six months after the last dose of vaccine))
HPV-16 and HPV-18 seropositivity rates and GMTs before the second dose of vaccine(One month after the second dose of vaccine, and six months after the last dose of vaccine)
Seropositivity rates to other defined HPV types and GMTs before the second dose of vaccine(One month after the second dose of vaccine and at one month and six months after the last dose of vaccine)
HPV-16 and -18 seropositivity rates and GMTs(One month after the last dose of vaccine)